Dr. Michael Gold, MD
Claim this profileOklahoma Cancer Specialists and Research Institute
Studies Ovarian Cancer
Studies Fallopian Tube Cancer
18 reported clinical trials
32 drugs studied
About Michael Gold, MD
Education:
- Obtained MD from the University of Oklahoma College of Medicine in 1987.
- Completed Residency in Internal Medicine at the University of Oklahoma Health Sciences Center in 1990.
- Finished Fellowship in Hematology/Oncology at the same institution in 1992.
Experience:
- Affiliated with Oklahoma Cancer Specialists and Research Institute.
- Specializes in medical oncology and hematology.
Area of expertise
1Ovarian Cancer
Stage IV
FRα positive
Stage III
2Fallopian Tube Cancer
FRα positive
Stage III
Stage IV
Affiliated Hospitals
Clinical Trials Michael Gold, MD is currently running
Alpelisib + Fulvestrant
for Endometrial Cancer
This trial tests a combination of two drugs, alpelisib and fulvestrant, in patients with a specific type of endometrial cancer. These patients have a genetic mutation (PIK3CA) and their cancer grows in response to estrogen. Alpelisib targets the mutation, while fulvestrant blocks estrogen, aiming to stop cancer growth. Alpelisib is the first drug of its kind approved for use with fulvestrant based on its effectiveness in treating similar types of cancer.
Recruiting1 award Phase 210 criteria
Mirvetuximab + Bevacizumab
for Ovarian Cancer
GLORIOSA is a Phase 3 multicenter, open label study designed to evaluate the safety and efficacy of mirvetuximab Soravtansine as maintenance therapy in participants with platinum-sensitive ovarian, primary peritoneal or fallopian tube cancers with high folate receptor-alpha (FRα) expression.
Recruiting2 awards Phase 3
More about Michael Gold, MD
Clinical Trial Related4 years of experience running clinical trials · Led 18 trials as a Principal Investigator · 4 Active Clinical TrialsTreatments Michael Gold, MD has experience with
- Paclitaxel
- Mirvetuximab Soravtansine
- Placebo
- Carboplatin
- Pegylated Liposomal Doxorubicin
- Topotecan
Breakdown of trials Michael Gold, MD has run
Ovarian Cancer
Fallopian Tube Cancer
Endometrial Cancer
Ovarian Tumors
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Michael Gold, MD specialize in?
Michael Gold, MD focuses on Ovarian Cancer and Fallopian Tube Cancer. In particular, much of their work with Ovarian Cancer has involved Stage IV patients, or patients who are FRα positive.
Is Michael Gold, MD currently recruiting for clinical trials?
Yes, Michael Gold, MD is currently recruiting for 4 clinical trials in Tulsa Oklahoma. If you're interested in participating, you should apply.
Are there any treatments that Michael Gold, MD has studied deeply?
Yes, Michael Gold, MD has studied treatments such as Paclitaxel, Mirvetuximab Soravtansine, Placebo.
What is the best way to schedule an appointment with Michael Gold, MD?
Apply for one of the trials that Michael Gold, MD is conducting.
What is the office address of Michael Gold, MD?
The office of Michael Gold, MD is located at: Oklahoma Cancer Specialists and Research Institute, Tulsa, Oklahoma 74146 United States. This is the address for their practice at the Oklahoma Cancer Specialists and Research Institute.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.